As of December 2023, DFMO won approval from the US Food and Drug Administration (FDA) for high-risk neuroblastoma as a maintenance therapy, and former patient Will Lacey is now a healthy college ...

Neuroblastoma may behave in an almost benign way, with spontaneous regression in some infants, but the majority of older patients have high-risk disease, which is usually fatal, despite best ...

We treat people of all ages and have experience managing every stage of neuroblastoma cancer, with special expertise in caring for those with aggressive disease and those whose cancer has come back.

Blocking the METTL3 protein can increase sensitivity to chemotherapy in neuroblastoma, according to new research. The study shows how specific RNA modifications affect gene expression in the early ...

Current high-risk neuroblastoma protocols involve a multimodality therapy approach and include an induction chemotherapy regime, surgical resection of the primary tumor, high-dose myeloablative ...

Blocking the METTL3 protein can increase sensitivity to chemotherapy in neuroblastoma, according to research from the ...

Its flagship drug, Omburtamab, was designed to target central nervous system and leptomeningeal metastases in pediatric neuroblastoma patients. Y-mAbs aimed to commercialize Omburtamab, promoting it ...

“Hu14.18 has enormous potential to help high-risk neuroblastoma patients, the majority of whom are young children,” she said. “We are now committed to developing this immunotherapy to be ...

Cancer statistics commonly use a five-year survival rate to indicate when a patient no longer has the disease. Around 40 ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

While the search for a cure continues, researchers at the University of South Australia are striving to decode the causes of neuroblastoma to inform new, less toxic treatment strategies for young ...